Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Running Python scripts is one of the most common tasks in automation. However, managing dependencies across different systems can be challenging. That’s where Docker comes in. Docker lets you package ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Visual Studio Code (VSCode) is a powerful, free source-code editor that makes it easy to write and run Python code. This guide will walk you through setting up VSCode for Python development, step by ...

A man from Savannah, GA, has been sentenced to 20 years in prison after pleading guilty to the stalking of a woman and the use of an explosive in a felony offense on Jan. 13, 2023. The man was also ...

One way to speed up your Python programs is to write modules in the Zig language and use them in your Python code. Here's how to get started. Python might not be the fastest of languages, but it has ...

Shareholders of Exponent Inc. (Symbol: EXPO) looking to boost their income beyond the stock's 1.2% annualized dividend yield can sell the June 2025 covered call at the $105 strike and collect the ...

An experimental ‘no-GIL’ build mode in Python 3.13 disables the Global Interpreter Lock to enable true parallel execution in Python. Here’s where to start. The single biggest new feature in Python ...

The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...

Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine ...